Key facts
- Forcast Orthopedics’s last known valuation is $25.5M (Jul 2025).
- It has raised $12.7M across 1 recorded rounds; the latest was Seed Round ($3.8M) in Aug 2025.
- Notable investors include US National Science Foundation, Colorado Venture Capital Authority, OrthoInnovations.
- Forcast Orthopedics has filed 1 Form D with the SEC, most recently Aug 2025 ($3.8M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Forcast Orthopedics
Funding rounds
1 roundsAbout Forcast Orthopedics
Developer of a proprietary automated drug device designed to deliver targeted antibiotic therapy for periprosthetic joint infections. The company's device modernizes the treatment approach for infections following joint replacement surgery by automating the process of giving antibiotics through an implant, enabling doctors to achieve superior patient outcomes with lower costs and reduced morbidity compared to traditional treatment methods.
- Sector
- Healthcare
- HQ
- Longmont, CO, United States
- Founded
- 2017
- Employees
- 4
- Website
- forcastortho.com/
- Ownership
- Privately Held (backing)
Forcast Orthopedics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forcast Orthopedics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forcast Orthopedics in its N-PORT filings yet. We sweep new filings monthly.